Since the derivation of human-derived embryonic stem cells (ES cells) in the 1990’s, the world of stem cell biology and engineering has proceeded at an amazing pace. The isolation pluripotent cells (iPS) cells that have most of the properties of embryonic stem cells from somatic tissues has been possible for nearly a decade. Engineered human cells, tissues, and organ-like structures are becoming a reality and may soon play a part in treating diseases. ES and iPS cells are teaching us much about how cells become specialized during normal development and the pathologies that result when those specialization decisions go wrong.
At the 12th Annual Wisconsin Stem Cell Symposium held at the BioPharmaceutical Technology Center institute, leading researchers from around the world will be gathered to discuss the latest progress, roadblocks and issues around Engineering Cells and Tissues for Discovery and Therapy.
The Symposium is co-coordinated by the Stem Cell & Regenerative Medicine Center at the University of Wisconsin-Madison and the BioPharmaceutical Technology Center Institute and is open to the public. Registration is $100.00 ($50.00 for students and post-doctoral researchers). The Symposium will be held at Promega Corporation’s BioPharmaceutical Technology Center, 5445 E. Cheryl Parkway, Fitchburg, WI.
Topics to be discussed include: Continue reading “Researchers Gather at Promega Madison Campus for Annual Stem Cell Symposium”